NICE recommends radium-223 dichloride
The National Institute of Health and Care Excellence has recommended radium-223 dichloride as an option for treating adults with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, only if they have had treatment with docetaxel and the company provides radium-223 dichloride with the discount agreed in the patient access scheme.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200583
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com